Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.55 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895301 | 0.91 | F2R (0.53) | F2RTACR1AKR1C3LIPEKMT2A | |
| SCHEMBL9894727 | 0.89 | F2R (0.55) | F2RTACR1AKR1C3KMT2ARORC | |
| SCHEMBL9895615 | 0.88 | F2R (0.58) | F2RTACR1AKR1C3KMT2ARORC | |
| SCHEMBL3723481 | 0.87 | F2R (0.56) | F2RTACR1AKR1C3LIPEKMT2A | |
| SCHEMBL9926858 | 0.86 | F2R (0.56) | F2RTACR1AKR1C3KMT2ARORC | |
| SCHEMBL9926855 | 0.86 | F2R (0.52) | F2RTACR1AKR1C3 | |
| SCHEMBL3797843 | 0.86 | F2R (0.59) | F2RTACR1AKR1C3LIPEKMT2A | |
| SCHEMBL3792551 | 0.84 | F2R (0.57) | F2RTACR1AKR1C3LIPEKMT2A | |
| SCHEMBL9926859 | 0.84 | F2R (0.50) | F2RTACR1AKR1C3KMT2ARORC | |
| SCHEMBL9926854 | 0.83 | F2R (0.55) | F2RTACR1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435428-B1 | SUBSTITUTED PIPERIDINES | BAYER IP GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120149694-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149694-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149694-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2010136128-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149694-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885TACR1 544/4885AKR1C3 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.